Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.

Transpl Infect Dis

Assistance Publique-Hôpitaux de Paris, CHU Bicêtre, Centre de Vaccinations Internationales, Service de Maladies Infectieuses et Tropicales, Le Kremlin-Bicêtre, France.

Published: April 2015

Immunization against meningococcal disease is recommended for solid organ transplant (SOT) recipients at high risk for meningococcal disease or travelling to an endemic country. However, the immunogenicity of meningococcal vaccines has not been studied in this population. We analyzed the immune response of quadrivalent (against Neisseria meningitidis serogroups A, C, Y, and W) polysaccharidic non-conjugate and conjugate meningococcal vaccines in kidney- and liver-transplant patients using bactericidal assays against the targeted serogroups. Upon vaccination with a non-conjugate (n = 5) or a conjugate vaccine (n = 10), respectively, 40% and 50% of patients were able to mount an immune response, achieving at least the threshold correlated with protection defined as human serum bactericidal antibody titers of ≥4. Responders showed only partial and low responses (titers ≤64), thus predicting a rapid decline in bactericidal response. Only 1 patient developed a booster response to preexisting immunity. Our data argue for the need of additional measures for SOT recipients, when they are at risk of meningococcal disease.

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.12359DOI Listing

Publication Analysis

Top Keywords

meningococcal vaccines
12
meningococcal disease
12
solid organ
8
organ transplant
8
sot recipients
8
risk meningococcal
8
immune response
8
meningococcal
6
low immunogenicity
4
immunogenicity quadrivalent
4

Similar Publications

Neisseria gonorrhoeae, which causes the sexually transmitted infection gonorrhea and Neisseria meningitidis, a leading cause of bacterial meningitis and septicemia, are closely related human-restricted pathogens that inhabit distinct primary mucosal niches. While successful vaccines against invasive meningococcal disease have been available for decades, the rapid rise in antibiotic resistance has led to an urgent need to develop an effective gonococcal vaccine. Several surface antigens are shared among these two pathogens, making cross-species protection an exciting prospect.

View Article and Find Full Text PDF

IgA1 protease is one of the virulence factors of , and other pathogens causing bacterial meningitis. The aim of this research is to create recombinant proteins based on fragments of the mature IgA1 protease A-P from serogroup B strain H44/76. These proteins are potential components of an antimeningococcal vaccine for protection against infections caused by pathogenic strains of and other bacteria producing serine-type IgA1 proteases.

View Article and Find Full Text PDF

Background: This study aims to evaluate parents' knowledge about vaccination targeted for adolescents.

Methods: The cross-sectional survey was conducted between February and April 2024 in a sample of parents of adolescents attending middle and high schools in Southern Italy.

Results: Only 10.

View Article and Find Full Text PDF

Characterization of Unusual Serogroups of .

Microorganisms

December 2024

Institut Pasteur, Invasive Bacterial Infections, Université Paris Cité, 75015 Paris, France.

Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the National Reference Center for Meningococci and in France between 2014 and 2023.

View Article and Find Full Text PDF

The genus Neisseria includes two major human pathogens: N. meningitidis causing bacterial meningitis/septicemia and N. gonorrhoeae causing gonorrhoea.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!